

CLIA WAIVED

# Xpert<sup>®</sup> Xpress Flu Xpert<sup>®</sup> Xpress Flu/RSV

Fast Diagnosis When it Matters Most



For *In Vitro* Diagnostic Use.

 **Cepheid**<sup>®</sup>  
A better way.



# Xpert<sup>®</sup> Xpress Flu Xpert<sup>®</sup> Xpress Flu/RSV



## The Need

- In patients of all ages, influenza and RSV often present with similar clinical symptoms, making it difficult to differentiate between the two infections<sup>1</sup>
- Sensitivities of rapid EIA Flu tests range from 50-70%<sup>2</sup>
- Sensitivities of rapid antigen RSV tests average 29% in adults<sup>3</sup>
- Both rapid EIA and antigen manufacturers suggest confirming negative results with RT-PCR or culture<sup>2</sup>
- Rapid RSV tests may have age limitations<sup>4</sup>

## The Solution

- Accurate and reliable detection of Flu A, Flu B and RSV in as soon as 20 minutes\*
- Enables healthcare providers to quickly deliver targeted therapies
- Streamlines laboratory operations
- Improves patient satisfaction

## The Impact

Single-test confidence will accelerate your laboratory's workflow with on-demand, random-access flexibility. Combine performance with the capability to run other Xpert<sup>®</sup> tests (including GBS, MRSA, *C. difficile*, CT/NG, and MTB/RIF) on Cepheid's GeneXpert<sup>®</sup> System to achieve proven productivity increases in overall laboratory service.<sup>5-9</sup>

### Be Proactive


- Achieve rapid results and improve patient management
- Early assay termination option: deliver positive results in as soon as 20 minutes\* and negative results in 30 minutes
- Quickly deliver targeted therapies and increase peace of mind for patients

\* With early assay termination (EAT) for positive Flu or for positive RSV only. Reporting negatives and combined Flu and RSV results in 30 minutes.


# Impact on Outpatient Pathway

## Improving Patient Satisfaction

Xpert® Xpress Flu and Xpert® Xpress Flu/RSV provides medically actionable and timely information to clinicians to support improved patient management and antibiotic and antiviral stewardship.



# Impact on Patient Admission & Management at Emergency Department



IC – Infection Control; ID – Infectious Disease

\* With early assay termination (EAT) for positive Flu or for positive RSV only. Reporting negatives and combined Flu and RSV results in 30 minutes.





# Xpert<sup>®</sup> Xpress

Powered by **Cepheid** Innovation

Cepheid products carrying the **Xpress** mark feature next-generation test design and cartridge innovations for dramatically faster results.

➤ **Xpert<sup>®</sup> Xpress Flu and Xpert<sup>®</sup> Xpress Flu/RSV** are qualitative real-time PCR tests providing accurate detection of Flu A, Flu B, and/or RSV in as soon as 20 minutes\*.

	CATALOG NUMBER
Xpert <b>Xpress</b> Flu (10 tests) . . . . .	XPRSFLU-10
Xpert <b>Xpress</b> Flu/RSV (10 tests) . . . . .	XPRSFLU/RSV-10
Nasal Swab & UTM (100 sets) . . . . .	SWAB/F-100
Nasopharyngeal Swab & UTM (100 sets) . . . . .	SWAB/B-100

## CPT Code Information

TEST NAME	DESCRIPTION	CPT CODE
Xpert <sup>®</sup> <b>Xpress</b> Flu	Influenza virus, for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, first 2 types or sub-types	<b>MODERATE:</b> 87502 <b>CLIA-WAIVED:</b> 87502-QW
Xpert <sup>®</sup> <b>Xpress</b> Flu/RSV	Respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets	<b>MODERATE:</b> 87631 <b>CLIA-WAIVED:</b> 87631-QW

\* With early assay termination (EAT) for positive Flu or for positive RSV only. Reporting negatives and combined Flu and RSV results in 30 minutes.

### References:

1. Falsey AR, Walsh EE. Respiratory Syncytial Virus Infection in Adults. Clin Microbiol Rev. 2000 Jul; 13.
2. CDC. Guidance for Clinicians on the Use of Rapid Influenza Diagnostic Tests. Accessed Sep 2016. [http://www.cdc.gov/flu/professionals/diagnosis/clinician\\_guidance\\_ridt.htm](http://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm)
3. Chartrand C, et al. Diagnostic Accuracy of Rapid Antigen Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and Meta-analysis. J Clin Microbiol. 2015 Dec;53(12):3738-49.
4. BD Veritor™ System – For Rapid Detection of Flu A+B. Package Insert. DB. Dublin, Ireland. 2014.
5. Morgan MG. The Perfect Storm. Cepheid Impact. 2012 Jun;2:4-7.
6. Parada JP. Increase Revenue and Improve Patient Safety. Cepheid Impact. 2012 Jun;2:8-11.
7. El Helali N. Less Uncertainty - Better Safety - More Healthy Newborns. Cepheid Impact. 2012 Jul;3:4-7.
8. Haynes L. The C. difficile Challenge. Cepheid Impact. 2012 Jul;3:10-15.
9. Parada JP. Improving Patient Safety. Cepheid Impact. 2012 Oct;4:8-11.

## For *In Vitro* Diagnostic Use.

<b>CORPORATE HEADQUARTERS</b>	<b>EUROPEAN HEADQUARTERS</b>	<a href="http://www.Cepheid.com">www.Cepheid.com</a>
904 Caribbean Drive Sunnyvale, CA 94089 USA	Vira Soleih 81470 Maurens-Scopont France	
TOLL FREE 1.888.336.2743	PHONE 33.563.82.53.00	
PHONE 1.408.541.4191	FAX 33.563.82.53.01	
FAX 1.408.541.4192		